Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Alpha Tryptase
2. Alpha Tryptases
3. Alpha-tryptase
4. Alpha-tryptases
5. Beta Tryptase
6. Beta Tryptases
7. Beta-tryptase
8. Beta-tryptases
9. Delta Tryptase
10. Delta Tryptases
11. Delta-tryptase
12. Delta-tryptases
13. Gamma Tryptase
14. Gamma Tryptases
15. Gamma-tryptase
16. Gamma-tryptases
17. Mast Cell Tryptase
18. Skin Tryptase
19. Tryptase, Skin
20. Tryptases
1. Acetic Acid;tert-butyl N-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(5-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
2. Tryptase From Human Lung, Buffered Aqueous Solution, >=5 Units/mg Protein
1. Trypsin Complex
| Molecular Weight | 725.8 g/mol |
|---|---|
| Molecular Formula | C35H47N7O10 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 16 |
| Exact Mass | 725.33844072 g/mol |
| Monoisotopic Mass | 725.33844072 g/mol |
| Topological Polar Surface Area | 274 Ų |
| Heavy Atom Count | 52 |
| Formal Charge | 0 |
| Complexity | 1220 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38288
Submission : 2023-05-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15047
Submission : 2000-09-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39350
Submission : 2024-01-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38457
Submission : 2023-06-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1537
Submission : 1970-06-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39076
Submission : 2023-10-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6298
Submission : 1986-04-23
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 367
Submission : 1960-02-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 162
Submission : 1955-01-27
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]JDMF
Culture medium/Culture additives Trypsin-EDTA, liquid A31476
Registration Number : 229MF40004
Registrant's Address : 3175 Staley Road Grand Island, New York 14072-0068
Initial Date of Registration : 2017-01-30
Latest Date of Registration : 2018-10-30
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
About the Company : The company is in the business of manufacturing and marketing botanical extracts and nutraceuticals formulations to both domestic and global customers. The products include health/...
About the Company : The company is a professional manufacturer of active biological extracts. We adhere to the market-oriented business philosophy. The international and domestic markets take advantag...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Through the acquisition, Sun Pharma strengthen its anti-inflammatory portfolio by adding Disperzyme (bromelain), Disperzyme-CD and Phlogam from Aksigen Hospital Care.
Lead Product(s): Bromelain,Trypsin,Rutin
Therapeutic Area: Neurology Brand Name: Disperzyme
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 30, 2023
Sun Pharma Acquires Disperzyme® and Phlogam® Brands to Strengthen Its Anti-Inflammatory Portfoli...
Details : Through the acquisition, Sun Pharma strengthen its anti-inflammatory portfolio by adding Disperzyme (bromelain), Disperzyme-CD and Phlogam from Aksigen Hospital Care.
Brand Name : Disperzyme
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
